In a bid to standardize one of neonatal intensive care’s most persistent dilemmas, researchers have introduced the BRONX PDA protocol and BRONX clinical scoring system (BCSS) for managing patent ductus arteriosus (PDA) in premature infants. The work, published in Journal of Perinatology, targets the challenge that PDA care can vary widely across hospitals, despite the condition’s central role in preterm morbidity.
PDA occurs when the fetal ductus arteriosus fails to close after birth, allowing abnormal blood flow between the aorta and pulmonary artery. In very preterm neonates, this can strain the heart, disrupt respiratory status, and complicate overall clinical trajectories. Historically, clinicians have relied on heterogeneous decision pathways—mixing echocardiographic impressions, hemodynamic assessments, and treatment thresholds—leading to inconsistent timing and selection of therapies.
The BRONX approach reframes management around “practice-based universality” by coupling a structured protocol with a bedside scoring system. BCSS is designed to quantify clinical and physiological signals associated with ductal significance, helping teams decide whether and when intervention is warranted. Instead of treating imaging outputs in isolation, the system aims to translate multimodal indicators into a single operational framework for escalation or watchful waiting.
A key technical emphasis is harmonizing assessment timing and decision points. The protocol specifies how clinicians should evaluate ductal impact and align subsequent management steps, reducing ambiguity during early postnatal windows. By doing so, it seeks to limit both overtreatment—exposing infants to unnecessary drug or procedure-related risks—and undertreatment, which may permit ongoing hemodynamic stress.
Although PDA management often involves pharmacologic closure (commonly with agents that modulate ductal patency), the BRONX strategy also supports a consistent pathway for selecting candidates for escalation. The scoring system provides an evidence-oriented rationale for progressing from monitoring to targeted therapy, with the goal of improving reproducibility across different care settings.
Importantly, the protocol is presented as adaptable for routine neonatal workflows, not merely as an academic algorithm. That design choice matters in fast-moving ICU environments, where clinicians must balance serial observations, evolving ventilation needs, and rapidly changing hemodynamics.
The results described in this publication suggest that structured scoring can support more coherent decision-making at the population level. If implemented broadly, the model could enable multicenter comparisons by aligning what “clinically significant PDA” means in practice.
As neonatal care increasingly moves toward standardized, data-driven protocols, the BRONX PDA framework stands out as an attempt to make PDA treatment decisions more transparent, timely, and transferable—an important step toward viral-style rapid dissemination of actionable clinical science.
Subject of Research: Patent ductus arteriosus (PDA) management in premature neonates
Article Title: Universal practice based management of patent ductus arteriosus in premature neonates in 2025: BRONX PDA protocol and BRONX clinical scoring system (BCSS).
Article References: Lisboa, P., Gada, J., Gaudig, A. et al. Journal of Perinatology (2026). https://doi.org/10.1038/s41372-026-02798-4
Image Credits: AI Generated
DOI: 10.1038/s41372-026-02798-4
Keywords: patent ductus arteriosus, premature neonates, clinical scoring system, protocol-based management, neonatal intensive care, BCSS
